Issue of Equity / Directors'

RNS Number : 1390B
Omega Diagnostics Group PLC
12 August 2008
 



Omega Diagnostics Group PLC 

12 August 2008 

 

 

Omega Diagnostics Group PLC ('the Company') 

Issue of Equity / Directors' Dealings / Total Voting Rights


Omega Diagnostics Group PLC announces that it has allotted a total of 757,213 new ordinary shares of 4p each (the 'Earn Out Shares'), being deferred consideration pursuant to an agreement entered into between the Company (then known as Quintessentially English Plc), Andrew Shepherd, Kieron Harbinson, Scottish Enterprise and Julie Anne Monks Shepherd on 23 August 2006 for the purchase of the entire issued share capital of Omega Diagnostics Limited (the 'Acquisition Agreement').  


The total earn out due to the vendors of Omega Diagnostics Limited under the Acquisition Agreement was determined to be £605,772. This has been satisfied by the allotment of the Earn Out Shares at a notional price of 80p per Earn Out Share.  The Earn Out Shares have been allotted as follows:


Shareholder

No. of Earn Out Shares Allotted 

Andrew Shepherd

401,133

Scottish Enterprise

226,540

Julie Monks-Shepherd

110,106

Kieron Harbinson

19,434


Andrew Shepherd and Kieron Harbinson are Directors of the Company and their resultant holdings of ordinary shares of 4p each in the Company ('Ordinary Shares') are as follows:


Shareholder

Previous holding of Ordinary Shares

No. of Earn Out Shares allotted

New holding of Ordinary Shares

% Revised issued share capital

Andrew Shepherd

918,697

401,133

1,319,830

8.44%

Kieron Harbinson

38,883

19,434

58,317

0.37%


The Earn Out Shares will rank equally with the existing Ordinary Shares of the Company.  Application has been made for the Earn Out Shares to be admitted to trading on AIM ('Admission'). Admission is expected to become effective on 18 August 2008. 


Following Admission the total number of Ordinary Shares in issue will be 15,632,907. There are no Ordinary Shares held in treasury, and therefore the total number of Ordinary Shares with voting rights in the Company will be 15,632,907.


The above figure of 15,632,907 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules. 


Contacts: 

 

Omega Diagnostics Group PLC 

Tel: 01259 763030 

 

Andrew Shepherd, Chief Executive 

Kieron Harbinson, Finance Director 

www.omegadiagnostics.com 

 

Landsbanki Securities (UK) Limited

Nominated Adviser & Broker


Jeff Keating / Simon Brown

Tel: 020 7426 9000

 

Parkgreen Communications Limited 

 

Ben Knowles 

T. 020 7933 8788 

Mob. 07900 346 978 

Ben.knowles@parkgreenmedia.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOESFASUESASELA
UK 100

Latest directors dealings